Tactile Systems

Tactile Systems Technology, Inc. is a medical technology company. It develops and provides innovative medical devices for the treatment of chronic diseases at home. The firm focus on advancing the standard of care in treating chronic diseases in the home setting to improve patient outcomes and quality of life and help control rising healthcare expenditures. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tactile Systems reports strong Q4 earnings, eyes growth and innovation

Tactile Systems delivered impressive Q4 2022 results with strong revenue growth, positive net income, and operational advancements, positioning the company for future success.
Strategic priorities for 2023 focus on sales team productivity, new product innovation, and operational efficiency, highlighting a commitment to sustained growth and market leadership.
Challenges include managing sales force turnover, supply chain constraints, and financial complexities post-2023, requiring proactive solutions and strategic decision-making.
Opportunities lie in capitalizing on revenue growth momentum, new product developments, and achieving an expanded adjusted EBITDA profile, signaling potential for continued success and value creation.

Tactile Systems reports robust Q1 growth, focuses on innovation

Tactile Systems delivered strong financial performance and operational advancements in Q1 2023, showcasing growth potential and a commitment to innovation and patient care.
While facing challenges in supply chain readiness and operational efficiency, the company's strategic focus on enhancing Medicare processes and product development presents opportunities for future success.
Overall, Tactile Systems' earnings call highlighted a positive trajectory with increased revenue guidance, product innovation, and a dedication to improving patient outcomes and support.

Tactile Systems (TCMD) reports strong Q2 earnings and growth outlook

Tactile Systems (TCMD) showcased robust financial performance, operational efficiency gains, and strategic talent additions in Q2 2023.
While facing challenges like AffloVest sales slowdown, the company raised revenue guidance and expects strong profitability with adjusted EBITDA of $25-27 million for 2023.
Opportunities lie in the head and neck trial's potential impact on revenue, Kylee app engagement benefits, and strategic priorities driving growth.

Tactile Systems reports revenue growth and strategic initiatives progress

Tactile Systems' Q3 performance showed revenue growth and improved profitability, supported by strategic initiatives and margin improvement efforts.
While facing challenges in AffloVest sales and patient acquisition, the company is optimistic about opportunities in therapy expansion and operational enhancements.
Consistent price increases and focus on technology-driven efficiencies are key strengths, with a focus on achieving ambitious 2025 targets.
Overall, Tactile Systems is navigating challenges while capitalizing on opportunities for growth and operational optimization.

Tactile Systems posts robust Q4 results, eyes growth opportunities

Tactile Systems delivered strong financial performance in Q4 2023, with revenue and net income growth. The company provided optimistic revenue guidance for 2024 and outlined strategic priorities for driving growth and enhancing customer experience. Challenges include anticipated headwinds and limited margin gains in the short term.

Tactile Systems reports Q1 growth, doubles EBITDA, eyes tech expansion

Tactile Systems reported solid financial performance with revenue growth and doubled adjusted EBITDA.
The company is strategically investing in tech advancements, new products, and expanding sales channels.
Challenges include addressing declining airway clearance revenues and optimizing sales rep impact.
Opportunities lie in expanding clinical trials, enhancing product user experience, and leveraging tech investments.

Tactile Systems (TCMD) reports robust Q2 earnings amidst Medicare challenges

Tactile Systems' Q2 2024 performance reflects solid financial growth and strategic initiatives. While facing challenges from Medicare documentation requirements, the company is focused on adapting to regulatory changes. Opportunities lie in capital allocation strategies, technology advancements, and market expansion efforts.

Tactile Systems reports Q3 growth, faces documentation challenges and opportunities

Tactile Systems delivered solid Q3 performance with revenue growth and improved EBITDA, despite challenges in sales productivity.
The company's strategic strengths lie in strong market demand, product innovation, and a shareholder-friendly capital allocation strategy.
Navigating challenges related to regulatory changes and operational efficiency while capitalizing on growth opportunities will be key for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

Are Investors Undervaluing Tactile Systems Technology (TCMD) Right Now?

Tactile Systems Technology (TCMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Tactile Systems Technology, Inc. (TCMD) Hit a 52 Week High, Can the Run Continue?

MINNEAPOLIS, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Piper Sandler 36th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from December 3rd – 5th. Management will participate in a fireside chat on Tuesday, December 3rd at 10:00 a.m. Central Time.

Tactile Medical to Present at the Piper Sandler 36th Annual Healthcare Conference

Tactile Systems Technology (TCMD) is a Zacks Rank #2 (Buy) that has an A for Value and a C for Growth.  The company develops medical devices for the treatment of chronic diseases at home.

Bull Of The Day: Tactile Systems Technology (TCMD)

Is Tactile Systems Technology (TCMD) Stock Undervalued Right Now?

MediaAlpha

Travelzoo

Trump's win and rate cut should benefit small businesses to a good extent. Five small-cap stocks to buy are: PBAM, MAX, TCMD, TZOO, SABK.

Trump's Win and Rate Cut to Benefit Small Businesses: 5 Top Picks

The consensus price target hints at a 45.9% upside potential for Tactile Systems Technology (TCMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Tactile Systems Technology (TCMD) Could Rally 45.9%: Here's is How to Trade

Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Kyle Bauser - B. Riley Operator Please standby.

Tactile Systems Technology, Inc. (TCMD) Q3 2024 Earnings Call Transcript

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.85 per share a year ago.

Tactile Systems Technology (TCMD) Tops Q3 Earnings Estimates

MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2024 and announced the adoption of a share repurchase program. Third Quarter 2024 Summary & Recent Business Highlights: Total revenue increased 5% year-over-year to $73.1 million Lymphedema product revenue increased 4% over Q3 2023 Airway clearance product revenue increased 10% over Q3 2023 Net income of $5.2 million versus $22.3 million in Q3 2023 Adjusted EBITDA of $10.7 million versus $7.7 million in Q3 2023 Operating cashflow of $24.3 million year-to-date, compared to $17.5 million in the prior year period Ended Q3 2024 with $82.1 million in cash and cash equivalents Launched Nimbl, our next-generation lymphedema therapy platform for upper extremity conditions Announced publication of positive clinical trial results in VA lymphedema patients using Flexitouch therapy Authorized a program to repurchase up to $30.0 million of the Company's common stock “In the third quarter, we delivered solid gross margin expansion, drove continued improvements in profitability, and achieved double-digit growth in both our commercial and VA lymphedema channels,” said Sheri Dodd, President and Chief Executive Officer of Tactile Medical.

Tactile Systems Technology, Inc. Reports Third Quarter 2024 Financial Results

Tactile Systems Technology (TCMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tactile Systems Technology (TCMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2024 financial results will be released after the market closes on Monday, November 4, 2024.

Tactile Medical to Release Third Quarter of Fiscal Year 2024 Financial Results on November 4, 2024

InfuSystem Hlds

The medical device market, a powerhouse sector, is projected to exceed $600 billion by 2025. This growth is fueled by a combination of factors, including an aging population, rising healthcare costs, and rapid technological advancements powered by advanced artificial intelligence (AI) and biotechnology.

The Future of Medical Devices: Two Strong Buys You Can't Miss

Initial Launch Focused on Treating Patients Suffering from Upper Extremity Lymphedema Initial Launch Focused on Treating Patients Suffering from Upper Extremity Lymphedema

Tactile Medical Launches Next-Generation Nimbl™ Lymphedema Platform

TCMD announces a new study evaluating Flexitouch. The study reveals significant improvements in health-related quality of life and clinical outcomes.

Tactile Medical Stock Rises After Positive Flexitouch Trial Results

Largest U.S. Prospective Clinical Trial Ever Conducted Demonstrated High Compliance with the Flexitouch® System and Significant Improvements Across Study Endpoints Largest U.S. Prospective Clinical Trial Ever Conducted Demonstrated High Compliance with the Flexitouch® System and Significant Improvements Across Study Endpoints

UPDATE -- Tactile Medical Announces Positive Clinical Trial Results in Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy

TCMD's Nimbl pneumatic compression system gets CMS PDAC approval and is set to be launched in the United States soon, following FDA clearance for treating lymphedema.

Tactile Medical's Shares Rise After PDAC Approval for Nimbl

The average of price targets set by Wall Street analysts indicates a potential upside of 57.3% in Tactile Systems Technology (TCMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Tactile Systems Technology (TCMD) Have the Potential to Rally 57.31% as Wall Street Analysts Expect?

After reaching an important support level, Tactile Systems Technology (TCMD) could be a good stock pick from a technical perspective. TCMD surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Tactile Systems Technology (TCMD) Recently Broke Out Above the 20-Day Moving Average

After reaching an important support level, Tactile Systems Technology (TCMD) could be a good stock pick from a technical perspective. TCMD surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

Tactile Systems Technology (TCMD) Crossed Above the 50-Day Moving Average: What That Means for Investors

Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Margaret Kaczor - William Blair Adam Maeder - Piper Sandler Suraj Kalia - Oppenheimer & Company Operator Welcome, ladies and gentlemen, to the Second Quarter 2024 Earnings Conference Call for Tactile Medical. At this time, all participants have been placed in a listen-only mode.

Tactile Systems Technology, Inc. (TCMD) Q2 2024 Earnings Call Transcript

Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.05 per share a year ago.

Tactile Systems Technology (TCMD) Q2 Earnings and Revenues Surpass Estimates

MINNEAPOLIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2024.

Tactile Systems Technology, Inc. Reports Second Quarter 2024 Financial Results

MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2024 financial results will be released after the market closes on Monday, August 5, 2024.

News for Tactile Systems Stock (TCMD)